Viridian Therapeutics, Inc.\DE (VRDN)

Viridian Therapeutics shares rose 3.09% to close at $30.19 after the company reported positive first-in-human trial results for VRDN-008, an early-stage drug candidate. The data showed that under-the-skin dosing lowered IgG levels deeply and durably for eight weeks, reaching a 74% reduction at the highest point, and the company is targeting an 8-week dosing schedule. While the trial is the earliest test stage and further studies lie ahead, the results were viewed favorably by the market. The stock traded between $28.60 and $30.38 on volume of over 3.8 million shares, signaling a bullish reaction to the news.

Viridian Therapeutics shares closed at $28.55, down 3.48% on the day, despite a wave of bullish analyst actions. Multiple firms reiterated positive ratings and raised price targets, including Leerink Partners to $54, Wedbush to $42, Truist to $42, RBC Capital to $41, Wells Fargo to $34, and Evercore ISI to $33. The stock traded between $28.48 and $29.61 on volume of 3.39 million shares. While the analyst upgrades signal confidence in the stock's value, the price decline suggests broader market or sector pressure outweighed the positive news.

Viridian Therapeutics shares closed up 2.79% at $29.05 after Needham reiterated its Buy rating and raised its price target to $38. The company also reported a third-quarter loss of $0.81 per share, narrower than the $1.00 loss estimate, though revenue of $25,752 was not comparable to the $5.084 million estimate. Viridian held a call to discuss its Q3 2026 results and filed a Form 8-K on a major company event. The bullish analyst action and better-than-expected loss signal positive momentum for the stock.